Bajaj Healthcare launches Favijaj tablets for Covid-19 treatment in India

Bajaj Healthcare Limited (BHL) has launched Favijaj tablets, its generic version of Japan-based Fujifilm’s antiviral drug favipiravir for the treatment of mild to moderate Covid-19 patients.

The launch follows approval from the Indian drug regulator to manufacture and market the Covid-19 medicine.

Favipiravir is an antiviral drug used for the treatment of influenza virus, which has been shown to be effective in fighting Covid-19 as well. In particular, the drug has been proven to have potential in vitro activity against severe acute respiratory syndrome of Covid-19.

Anil Jain – Joint Managing Director of Bajaj Healthcare said: “We are pleased to add Favipiravir to our growing product portfolios.

“The second wave is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure, and offer patients much needed and timely therapy option.”

Bajaj Healthcare said that it has developed the active pharmaceutical ingredient (API) and the formulation for favipiravir successfully through its own in-house research and development team.

The company said that its Covid-19 drug can be purchased as a prescription-based medication, with recommended doses.